Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...